Highlights

• This study demonstrates that glycemic control with exenatide monotherapy is similar among normal-weight, overweight, and obese Chinese patients with newly diagnosed type 2 diabetes (T2D). Body weight decreased by 3.7%, 5.5%, and 5.7% in normal-weight, overweight, and obese patients, respectively.
• Hence, normal-weight patients with T2D would benefit from exenatide as much as overweight or obese patients on glucose control, without an increased risk of excess weight loss.

Highlights

• Since the PK/PD of U-500 regular insulin more closely resembles that of NPH insulin, it is commonly given before breakfast and dinner.
• However, a delayed response in which the major effect of the concentrated insulin takes place overnight occurs in about 10% of patients.
• This necessitates converting the regimen to a basal/bolus one in which the before breakfast injection serves as the basal insulin and short- or rapid-acting insulin is given before meals to control daytime hyperglycemia.

Highlights

• Diabetes in developing countries is increasing and often undiagnosed. In South Asians, diabetes and related metabolic abnormalities develop at a younger age and at a lower body mass index and waist circumference than in Whites.
• Overall glycemic control and management of diabetes is suboptimal, driven by multiple factors (eg, unawareness, cost of drugs and insulin etc.), and the load of complications is high.
• To stem this epidemic, strong actions for prevention and management are required using innovative and low-cost approaches.

Highlights

• Jinlida granules as an add-on therapy had additional benefits of for type 2 diabetes (T2D) and were generally safe.
• Jinlida granules showed clinically and statistically significant reductions in fasting plasma glucose, 2-hour post-load glucose, and HbA1c in T2D, with high-quality evidence.
• Jinlida granules may be used as a complementary and alternative approach for regulating glucose levels in patients with T2D.

Highlights

• Medication utilization trends for type 2 diabetes have changed significantly over the years with a shift towards newer agents, and in line with prevailing treatment guidelines.
• Metformin is currently the most commonly prescribed glucose-lowering agent, while the use of insulin has increased tremendously in our institution. Use of sulfonylureas decreased, but to a lesser extent than other studies.
• Glycemic control has remained largely stable throughout the 11-year study period, but the rate of severe hypoglycemia has increased.

Highlights

• The results of this paper is a post-hoc analysis of the original Da Qing Prevention Study.
• The findings showed that hypertension per se not only led to a higher incidence of cardio-cerebral-vascular disease, but also increased the risk of cardiovascular disease events by accelerating the development of diabetes among subjects with impaired glucose tolerance.
• It suggested that an individualized intervention targeting to control hypertension together with preventing the development of diabetes may favor the reduction of the diabetes-related macro-complications among the impaired glucose tolerance population with hypertension.